Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis

Hayashi,Hironori; Amaya,Koji; Tokoro,Tomokazu; Mori,Kosuke; Takenaka,Shunsuke; Sugimoto,Yuya; Kitano,Yuto; Kurata,Toru; Kawai,Shunsuke; Hirose,Atsushi; Tsukada,Tomoya; Kaji,Masahide; Shimizu,Koichi; Maeda,Kiichi

doi:10.3892/mco.2021.2335

Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis

Authors:
- Hironori Hayashi
- Koji Amaya
- Tomokazu Tokoro
- Kosuke Mori
- Shunsuke Takenaka
- Yuya Sugimoto
- Yuto Kitano
- Toru Kurata
- Shunsuke Kawai
- Atsushi Hirose
- Tomoya Tsukada
- Masahide Kaji
- Koichi Shimizu
- Kiichi Maeda
View Affiliations

Affiliations: Department of Surgery, Toyama Prefectural Central Hospital, Toyama 930‑8550, Japan, Department of Surgery, Kaga Medical Center, Kaga, Ishikawa 922‑8522, Japan
Published online on: June 29, 2021 https://doi.org/10.3892/mco.2021.2335
Article Number: 173
Copyright: © Hayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with pancreatic ductal adenocarcinoma (PDAC) that have a history of other primary malignancies are not well documented. The current study therefore aimed to evaluate the clinicopathological characteristics of patients with PDAC with or without a history of other primary malignancies. A total of 102 patients with surgically treated PDAC that presented with or without a history of other primary malignancies were retrospectively analyzed. A total of 25 patients (24.5%) had a history of other primary malignancies (age, with history of other primary malignancy vs. without, 74.2 vs. 68.9 years; P=0.005) and the reason for consultation (P<0.001) differed significantly between the groups with a history of other primary malignancies [HoM(+)] and without a history of other primary malignancies [HoM(‑)]. Incidental indications during malignancy follow‑up was the most common reason for the diagnosis of PDAC in the HoM(+) group. Conversely, there were no significant differences in the resectability (P=0.645), complete resection rate (P=0.774) and final stage (P=0.474) between the two groups. Disease‑free survival was also not significantly different between the two groups (P=0.184). However, overall survival was significantly poorer in the HoM(+) group compared with the HoM(‑) group (P=0.003). A history of other primary malignancies was also an independent predictor of poor overall survival (hazard ratio, 2.416; 95% confidence interval, 1.324‑4.406; P=0.004). In conclusion, patients with PDAC and a history of other primary malignancies had significantly poorer overall survival than their counterparts, despite no differences in disease‑free survival.

View Figures

View References

1	Buscail L, Bournet B and Cordelier P: Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 17:153–168. 2020.PubMed/NCBI View Article : Google Scholar
2	Kanno A, Masamune A, Hanada K, Kikuyama M and Kitano M: Advances in early detection of pancreatic cancer. Diagnostics (Basel). 9(18)2019.PubMed/NCBI View Article : Google Scholar
3	Unno M, Motoi F, Matsuyama Y, Satoi S, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H, et al: Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol. 37 (Suppl 4)(S189)2019.PubMed/NCBI View Article : Google Scholar
4	Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, et al: Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): A randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 3:413–423. 2018.PubMed/NCBI View Article : Google Scholar
5	Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016.PubMed/NCBI View Article : Google Scholar
6	Ocuin LM, Miller-Ocuin JL, Zenati MS, Vargo JA, Singhi AD, Burton SA, Bahary N, Hogg ME, Zeh HJ III and Zureikat AH: A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Oncol. 8:696–704. 2017.PubMed/NCBI View Article : Google Scholar
7	Raff JP, Noyer C, Boxer N, Sadan S, Costin D, Roayaie S, Gordon M, Kaumaya M, Hopkins U, Cortese M, et al: Early detection for pancreatic cancer in individuals at elevated-risk, using endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI) of the abdomen: Feasibility and preliminary outcomes. J Clin Oncol. 38 (Suppl 15)(e16798)2020.
8	Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, et al: Familial pancreatic cancer: Concept, management and issues. World J Gastroenterol. 23:935–948. 2017.PubMed/NCBI View Article : Google Scholar
9	Ohmoto A, Yachida S and Morizane C: Genomic features and clinical management of patients with hereditary pancreatic cancer syndromes and familial pancreatic cancer. Int J Mol Sci. 20(561)2019.PubMed/NCBI View Article : Google Scholar
10	Llach J, Carballal S and Moreira L: Familial pancreatic cancer: Current perspectives. Cancer Manag Res. 12:743–758. 2020.PubMed/NCBI View Article : Google Scholar
11	Shin SJ, Park H, Sung YN, Yoo C, Hwang DW, Park JH, Kim KP, Lee SS, Ryoo BY, Seo DW, et al: Prognosis of pancreatic cancer patients with synchronous or metachronous malignancies from other organs is better than those with pancreatic cancer only. Cancer Res Treat. 50:1175–1185. 2018.PubMed/NCBI View Article : Google Scholar
12	Eriguchi N, Aoyagi S, Hara M, Okuda K, Tamae T, Fukuda S, Hashino K, Sato S, Fujiki K, Furukawa S and Jimi A: Synchronous or metachronous double cancers of the pancreas and other organs: Report on 12 cases. Surg Today. 30:718–721. 2000.PubMed/NCBI View Article : Google Scholar
13	Gerdes B, Ziegler A, Ramaswamy A, Wild A, Langer P and Bartsch DK: Multiple primaries in pancreatic cancer patients: Indicator of a genetic predisposition? Int J Epidemiol. 29:999–1003. 2000.PubMed/NCBI View Article : Google Scholar
14	Wang Z, Zhou Y, Guan C, Ding Y, Tao S, Huang X, Chen L, Zhang F and Zhang R: The impact of previous cancer on overall survival of bladder cancer patients and the establishment of nomogram for overall survival prediction. Medicine (Baltimore). 99(e22191)2020.PubMed/NCBI View Article : Google Scholar
15	Brierley JD, Gospodarowicz MK and Wittekind C (eds): TNM Classification of Malignant Tumours. 8th edition. John Wiley & Sons, Toyama, Toyama, pp930-8550, 2017.
16	He X, Li Y, Su T, Lai S, Wu W, Chen L, Si J and Sun L: The impact of a history of cancer on pancreatic ductal adenocarcinoma survival. United European Gastroenterol J. 6:888–894. 2018.PubMed/NCBI View Article : Google Scholar
17	Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I and Ogata Y: Outcomes in patients with pancreatic cancer as a secondary malignancy: A retrospective single-institution study. Langenbecks Arch Surg. 404:975–983. 2019.PubMed/NCBI View Article : Google Scholar
18	Adamska A, Domenichini A and Falasca M: Pancreatic ductal adenocarcinoma: Current and evolving therapies. Int J Mol Sci. 18(1338)2017.PubMed/NCBI View Article : Google Scholar
19	Asari S, Matsumoto I, Toyama H, Shinzeki M, Goto T, Ishida J, Ajiki T, Fukumoto T and Ku Y: Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: The neutrophil-lymphocyte and platelet-lymphocyte ratios. Surg Today. 46:583–592. 2016.PubMed/NCBI View Article : Google Scholar
20	Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL and Hruban RH: Genetic basis of pancreas cancer development and progression: Insights from whole-exome and whole-genome sequencing. Clin Cancer Res. 18:4257–4265. 2012.PubMed/NCBI View Article : Google Scholar
21	Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321:1801–1806. 2008.PubMed/NCBI View Article : Google Scholar
22	Le A, Rajeshkumar NV, Maitra A and Dang CV: Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res. 18:4285–4290. 2012.PubMed/NCBI View Article : Google Scholar
23	Neureiter D, Jäger T, Ocker M and Kiesslich T: Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects. World J Gastroenterol. 20:7830–7848. 2014.PubMed/NCBI View Article : Google Scholar
24	Guo M, Jia Y, Yu Z, House MG, Esteller M, Brock MV and Herman JG: Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas. Discov Med. 17:67–73. 2014.PubMed/NCBI
25	Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005.PubMed/NCBI View Article : Google Scholar
26	Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, et al: Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 10:3–8. 2011.PubMed/NCBI View Article : Google Scholar